Lung immune defences after stimulation of gut-associated lymphoid tissue with OM-85 BV: A double-blind study in patients with chronic bronchitis

M. Lusuardi, A. Capelli, C. F. Donner

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A placebo-controlled, double-blind, parallel-group study was carried out to evaluate whether oral administration of OM-85 BV can lead to significant immune modifications in the respiratory tract of patients suffering from chronic bronchitis. Ten patients (aged 61 ± 2 yrs; forced expiratory volume in one second (FEV1) 64 ± 4 predicted and forced vital capacity (FVC) 74 ± 5% pred; mean ± SEM) received active treatment, and 10 patients (66 ± 1 yrs, FEV1 67 ± 6% pred and FVC 78 ± 5% pred) placebo. On entry (To) and 90 days after beginning treatment (T90), all patients underwent bronchoalveolar lavage (BAL). In an open follow-up, nine of the placebo group patients were subsequently treated with OM-85 BV for 3 months (T90-T180). BAL recoveries, cellularity, fell differentials and lymphocyte subsets did not show significant differences. Absolute levels of immunoglobulin (Ig)A, but not IgG, significantly increased after treatment with OM-85 BV. IgA/albumin ratios were not significantly different, but IgA/albumin was significantly higher in the treatment vs the placebo group when data from current smokers were excluded. Functional tests on alveolar macrophages (AMs) showed a significant increase of random motility and of stimulated motility after challenge with a formyl-peptide, plus a significant increase of superoxide anion (O2-) as spontaneous release and after stimulation with opsonized zymosan in the treatment group only. In the comparison of T90 vs T180 data, a significant increase both of spontaneous and stimulated O2- release was found. No modifications in systemic immunity were observed. In conclusion, oral administration of OM-85 BV can increase immune defences in the respiratory tract of patients with chronic bronchitis, without apparently altering systemic immunity. Our data support the role of OM-85 BV in prevention of chronic bronchitis exacerbations.

Original languageEnglish
Pages (from-to)182-185
Number of pages4
JournalEuropean Respiratory Review
Volume6
Issue number36
Publication statusPublished - 1996

Fingerprint

Chronic Bronchitis
Lymphoid Tissue
Double-Blind Method
Lung
Placebos
Immunoglobulin A
Vital Capacity
Bronchoalveolar Lavage
Respiratory System
Oral Administration
Albumins
Immunity
Therapeutics
Zymosan
Lymphocyte Subsets
Forced Expiratory Volume
Alveolar Macrophages
Superoxides
Broncho-Vaxom
Immunoglobulin G

Keywords

  • Bacterial extracts (OM-85 BV)
  • Biological response modifiers
  • Bronchoalveolar lavage
  • Chronic bronchitis
  • Immunostimulating agents
  • Recurrent exacerbations

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

@article{0a7d41aeee694a02ae23b4c9eafce3e2,
title = "Lung immune defences after stimulation of gut-associated lymphoid tissue with OM-85 BV: A double-blind study in patients with chronic bronchitis",
abstract = "A placebo-controlled, double-blind, parallel-group study was carried out to evaluate whether oral administration of OM-85 BV can lead to significant immune modifications in the respiratory tract of patients suffering from chronic bronchitis. Ten patients (aged 61 ± 2 yrs; forced expiratory volume in one second (FEV1) 64 ± 4 predicted and forced vital capacity (FVC) 74 ± 5{\%} pred; mean ± SEM) received active treatment, and 10 patients (66 ± 1 yrs, FEV1 67 ± 6{\%} pred and FVC 78 ± 5{\%} pred) placebo. On entry (To) and 90 days after beginning treatment (T90), all patients underwent bronchoalveolar lavage (BAL). In an open follow-up, nine of the placebo group patients were subsequently treated with OM-85 BV for 3 months (T90-T180). BAL recoveries, cellularity, fell differentials and lymphocyte subsets did not show significant differences. Absolute levels of immunoglobulin (Ig)A, but not IgG, significantly increased after treatment with OM-85 BV. IgA/albumin ratios were not significantly different, but IgA/albumin was significantly higher in the treatment vs the placebo group when data from current smokers were excluded. Functional tests on alveolar macrophages (AMs) showed a significant increase of random motility and of stimulated motility after challenge with a formyl-peptide, plus a significant increase of superoxide anion (O2-) as spontaneous release and after stimulation with opsonized zymosan in the treatment group only. In the comparison of T90 vs T180 data, a significant increase both of spontaneous and stimulated O2- release was found. No modifications in systemic immunity were observed. In conclusion, oral administration of OM-85 BV can increase immune defences in the respiratory tract of patients with chronic bronchitis, without apparently altering systemic immunity. Our data support the role of OM-85 BV in prevention of chronic bronchitis exacerbations.",
keywords = "Bacterial extracts (OM-85 BV), Biological response modifiers, Bronchoalveolar lavage, Chronic bronchitis, Immunostimulating agents, Recurrent exacerbations",
author = "M. Lusuardi and A. Capelli and Donner, {C. F.}",
year = "1996",
language = "English",
volume = "6",
pages = "182--185",
journal = "European Respiratory Review",
issn = "0905-9180",
publisher = "European Respiratory Society",
number = "36",

}

TY - JOUR

T1 - Lung immune defences after stimulation of gut-associated lymphoid tissue with OM-85 BV

T2 - A double-blind study in patients with chronic bronchitis

AU - Lusuardi, M.

AU - Capelli, A.

AU - Donner, C. F.

PY - 1996

Y1 - 1996

N2 - A placebo-controlled, double-blind, parallel-group study was carried out to evaluate whether oral administration of OM-85 BV can lead to significant immune modifications in the respiratory tract of patients suffering from chronic bronchitis. Ten patients (aged 61 ± 2 yrs; forced expiratory volume in one second (FEV1) 64 ± 4 predicted and forced vital capacity (FVC) 74 ± 5% pred; mean ± SEM) received active treatment, and 10 patients (66 ± 1 yrs, FEV1 67 ± 6% pred and FVC 78 ± 5% pred) placebo. On entry (To) and 90 days after beginning treatment (T90), all patients underwent bronchoalveolar lavage (BAL). In an open follow-up, nine of the placebo group patients were subsequently treated with OM-85 BV for 3 months (T90-T180). BAL recoveries, cellularity, fell differentials and lymphocyte subsets did not show significant differences. Absolute levels of immunoglobulin (Ig)A, but not IgG, significantly increased after treatment with OM-85 BV. IgA/albumin ratios were not significantly different, but IgA/albumin was significantly higher in the treatment vs the placebo group when data from current smokers were excluded. Functional tests on alveolar macrophages (AMs) showed a significant increase of random motility and of stimulated motility after challenge with a formyl-peptide, plus a significant increase of superoxide anion (O2-) as spontaneous release and after stimulation with opsonized zymosan in the treatment group only. In the comparison of T90 vs T180 data, a significant increase both of spontaneous and stimulated O2- release was found. No modifications in systemic immunity were observed. In conclusion, oral administration of OM-85 BV can increase immune defences in the respiratory tract of patients with chronic bronchitis, without apparently altering systemic immunity. Our data support the role of OM-85 BV in prevention of chronic bronchitis exacerbations.

AB - A placebo-controlled, double-blind, parallel-group study was carried out to evaluate whether oral administration of OM-85 BV can lead to significant immune modifications in the respiratory tract of patients suffering from chronic bronchitis. Ten patients (aged 61 ± 2 yrs; forced expiratory volume in one second (FEV1) 64 ± 4 predicted and forced vital capacity (FVC) 74 ± 5% pred; mean ± SEM) received active treatment, and 10 patients (66 ± 1 yrs, FEV1 67 ± 6% pred and FVC 78 ± 5% pred) placebo. On entry (To) and 90 days after beginning treatment (T90), all patients underwent bronchoalveolar lavage (BAL). In an open follow-up, nine of the placebo group patients were subsequently treated with OM-85 BV for 3 months (T90-T180). BAL recoveries, cellularity, fell differentials and lymphocyte subsets did not show significant differences. Absolute levels of immunoglobulin (Ig)A, but not IgG, significantly increased after treatment with OM-85 BV. IgA/albumin ratios were not significantly different, but IgA/albumin was significantly higher in the treatment vs the placebo group when data from current smokers were excluded. Functional tests on alveolar macrophages (AMs) showed a significant increase of random motility and of stimulated motility after challenge with a formyl-peptide, plus a significant increase of superoxide anion (O2-) as spontaneous release and after stimulation with opsonized zymosan in the treatment group only. In the comparison of T90 vs T180 data, a significant increase both of spontaneous and stimulated O2- release was found. No modifications in systemic immunity were observed. In conclusion, oral administration of OM-85 BV can increase immune defences in the respiratory tract of patients with chronic bronchitis, without apparently altering systemic immunity. Our data support the role of OM-85 BV in prevention of chronic bronchitis exacerbations.

KW - Bacterial extracts (OM-85 BV)

KW - Biological response modifiers

KW - Bronchoalveolar lavage

KW - Chronic bronchitis

KW - Immunostimulating agents

KW - Recurrent exacerbations

UR - http://www.scopus.com/inward/record.url?scp=0029818475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029818475&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029818475

VL - 6

SP - 182

EP - 185

JO - European Respiratory Review

JF - European Respiratory Review

SN - 0905-9180

IS - 36

ER -